These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 3169807)

  • 1. Phenotypic cyclophosphamide resistance in mouse myeloma hybridomas.
    Frondoza CG; DiSanto JP; Humphrey RL
    Hybridoma; 1988 Aug; 7(4):397-405. PubMed ID: 3169807
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development and characterization of a cyclophosphamide-resistant mouse plasmacytoma cell line.
    Frondoza CG; Trivedi SM; Humphrey RL
    Cancer Treat Rep; 1982 Jul; 66(7):1535-44. PubMed ID: 7093969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enhanced formation of mouse hybridomas without hat treatment in a serum-free medium.
    Yabe N; Matsuya Y; Yamane I; Takada M
    In Vitro Cell Dev Biol; 1986 Jul; 22(7):363-8. PubMed ID: 3733634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of cyclophosphamide on the immune response of BALB/c mice bearing an immunoglobulin M plasmacytoma (TEPC-183).
    Havas HF; Schiffman G
    Cancer Res; 1981 Mar; 41(3):801-7. PubMed ID: 7459867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction by cyclophosphamide administration of two distinct anti-tumor effector cells at tumor site and spleen of mice transplanted with MOPC-104E plasmacytoma.
    Nio Y; Ohgaki K; Tobe T
    J Clin Lab Immunol; 1989 May; 29(1):37-43. PubMed ID: 2534133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of antitumor immunity in cyclophosphamide-induced rejection of subcutaneous nonpalpable MOPC-315 tumors.
    Mokyr MB; Hengst JC; Dray S
    Cancer Res; 1982 Mar; 42(3):974-9. PubMed ID: 6977410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Detection of residual murine LPC-1 myeloma cells from bone marrow cell mixture after purging by 4-hydroperoxycyclophosphamide.
    Frondoza CG; Sinha S; Trivedi SM; Humphrey RL; Colvin OM
    Exp Hematol; 1987 Jul; 15(6):715-8. PubMed ID: 3297761
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cooperation between cyclophosphamide tumoricidal activity and host antitumor immunity in the cure of mice bearing large MOPC-315 tumors.
    Hengst JC; Mokyr MB; Dray S
    Cancer Res; 1981 Jun; 41(6):2163-7. PubMed ID: 7016310
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
    Mokyr MB; Ye QW
    Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type C virus particles in X63-Ag8.653 mouse plasmacytoma cells and in hybridomas derived from it.
    Rudolph M; Karsten U; Micheel B
    Arch Geschwulstforsch; 1983; 53(6):513-9. PubMed ID: 6670912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
    Ye QW; Mokyr MB
    Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Some advantages of curing mice bearing a large subcutaneous MOPC-315 tumor with a low dose rather than a high dose of cyclophosphamide.
    Mokyr MB; Dray S
    Cancer Res; 1983 Jul; 43(7):3112-9. PubMed ID: 6850619
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Temporary disappearance ("eclipse") of LPC-1 plasmacytoma M component synthesis following tumor cell transfer.
    Frondoza CG; Trivedi SM; Humphrey RL
    Cancer Res; 1979 Jul; 39(7 Pt 1):2497-500. PubMed ID: 445451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Fetal liver transplantation in mice: tolerance induction by portal venous inoculation with allogeneic cells followed by injection of cyclophosphamide].
    Yin HJ
    Zhonghua Yi Xue Za Zhi; 1992 Oct; 72(10):608-11, 639-40. PubMed ID: 1363694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion of plasmacytoma and host cells in vivo: selection of proliferating and nonproliferating cultures.
    Ber R; Lanir N
    J Natl Cancer Inst; 1984 Feb; 72(2):403-9. PubMed ID: 6582325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of repeated exposure to cyclophosphamide on drug resistance and biological properties of a newly autonomy-acquired mouse mammary tumor (T4-OI320).
    Takeda Y; Matsuzawa A; Kaneko T; Sekiguchi M; Fujii G
    Jpn J Exp Med; 1988 Apr; 58(2):87-98. PubMed ID: 2842525
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenic and nondividing mafosfamide-treated L 1210 cells--comparison of lines resistant and nonresistant to cyclophosphamide.
    Kawalec M; Hoser G; Skórski T; Kawiak J
    Folia Histochem Cytobiol; 1993; 31(2):63-6. PubMed ID: 8405569
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic cell hybrid selection with a transfectable dominant marker.
    Riera FC; Blam SB; Teng NN; Kaplan HS
    Somat Cell Mol Genet; 1984 Mar; 10(2):123-7. PubMed ID: 6324391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hybrid resistance to BALB/c plasmacytomas: F1 hybrid anti-MPC-11 immunological responses correlated with resistance to tumor challenge.
    Marsili MA; Walker MC; Phillips-Quagliata JM
    Cancer Res; 1986 Jan; 46(1):190-7. PubMed ID: 3484380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Importance of signaling via the IFN-alpha/beta receptor on host cells for the realization of the therapeutic benefits of cyclophosphamide for mice bearing a large MOPC-315 tumor.
    Mokyr MB; Place AT; Artwohl JE; Valli VE
    Cancer Immunol Immunother; 2006 Apr; 55(4):459-68. PubMed ID: 15965646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.